<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05796115</url>
  </required_header>
  <id_info>
    <org_study_id>PROPOSE02</org_study_id>
    <nct_id>NCT05796115</nct_id>
  </id_info>
  <brief_title>PROcalcitonin and Presepsin-guided Decision for Antibiotic Prophylaxis of EOS</brief_title>
  <acronym>PROPOSE</acronym>
  <official_title>PROcalcitonin and Presepsin-guided Decision for Antibiotic Prophylaxis of Early-Onset SEpsis in Preterm Infants: a Multicentre, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this randomized controlled study is to compare the outcome of preterm infants who&#xD;
      will receive the standard antibiotic prophylaxis for EOS or Procalcitonin/Presepsin-guided&#xD;
      antibiotic prophylaxis of early onset sepsis (EOS).&#xD;
&#xD;
      The main question it aims to answer is:&#xD;
&#xD;
      • Does Procalcitonin/Presepsin-guided antibiotic prophylaxis of (EOS) increase survival&#xD;
      without major morbidities, including IVH &gt;3 grade, PVL, ROP &gt;3 grade in either eye, NEC &gt;2&#xD;
      grade, BPD, or LOS.&#xD;
&#xD;
      Infants with gestational age between 25+0 and 31+6 weeks of gestation or a birth weight &lt;1500&#xD;
      g will be eligible for enrollment in the study.&#xD;
&#xD;
      Participants will be randomized to receive standard antibiotic prophylaxis for EOS (standard&#xD;
      group) or to receive antibiotic prophylaxis for EOS on the basis of PCT/P-SEP measured within&#xD;
      3 h of life (intervention group).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2023</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without major morbidities.</measure>
    <time_frame>Participants will be monitored for the duration of hospital stay which is an average of 10 weeks</time_frame>
    <description>Survival without IVH &gt;/=3 grade, PVL, ROP &gt;3 grade in either eye, NEC &gt;2 grade, BPD, or LOS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual components of the composite primary outcome will be regarded as secondary outcomes.</measure>
    <time_frame>Participants will be monitored for the duration of hospital stay which is an average of 10 weeks</time_frame>
    <description>Occurrence of IVH &gt;/=3 grade, PVL, ROP &gt;3 grade in either eye, NEC &gt;2 grade, BPD, or LOS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Early-Onset Neonatal Sepsis</condition>
  <arm_group>
    <arm_group_label>Antibiotic prophylaxis for EOS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS</intervention_name>
    <description>Infants will receive antibiotic prophylaxis for EOS on the basis of Procalcitonin and Presepsin values measured within the first 3 hours of life.</description>
    <arm_group_label>Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Antibiotic prophylaxis for EOS</intervention_name>
    <description>Infants will receive antibiotic prophylaxis for EOS.</description>
    <arm_group_label>Antibiotic prophylaxis for EOS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  infants of 25+0- 31+6 weeks of gestational age will be enrolled in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Risk factors for EOS:&#xD;
&#xD;
               -  maternal GBS colonization without adequate prophylaxis;&#xD;
&#xD;
               -  clinical chorioamnionitis diagnosed by maternal intrapartum fever (either a&#xD;
                  single documented maternal intrapartum temperature of ≥39.0°C or a temperature of&#xD;
                  38.0-38.9°C that persists for &gt;30 minutes) and 1 or more of the following: (1)&#xD;
                  maternal leukocytosis, (2) purulent cervical drainage, and (3) fetal tachycardia;&#xD;
&#xD;
               -  pre-labor rupture of membranes (ROM) &gt;1 h before delivery.&#xD;
&#xD;
          -  Surgery within the first week of life,&#xD;
&#xD;
          -  major congenital malformations,&#xD;
&#xD;
          -  chromosomal syndromes,&#xD;
&#xD;
          -  inherited metabolic disorders,&#xD;
&#xD;
          -  fetal hydrops&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Hours</minimum_age>
    <maximum_age>3 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlo Dani</last_name>
    <phone>0039 055 7948421</phone>
    <email>carlo.dani@unifi.it</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 8, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>Carlo Dani</investigator_full_name>
    <investigator_title>Full Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Early-Onset Sepsis</keyword>
  <keyword>Procalcitonin</keyword>
  <keyword>Presepsin</keyword>
  <keyword>Preterm infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

